Patents by Inventor Peter Kratzsch

Peter Kratzsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11169146
    Abstract: Herein is reported a method for the detection of a sortase in a sample, comprising the following steps: a) incubating the sample with a first substrate comprising an immobilization tag and a second substrate comprising a detectable label, whereby in the presence of a sortase in the sample a conjugate comprising the immobilization tag and the detectable label is formed, b) immobilizing the conjugate of step a) via/using the immobilization tag to a solid phase, c) detecting the immobilized conjugate via/using the detectable label and thereby detecting the sortase in the sample.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 9, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Mara Boenitz-Dulat, Erhard Kopetzki, Peter Kratzsch, Martin Schatte
  • Patent number: 10704029
    Abstract: The present invention relates to a mutant 3-hydroxybutyrate dehydrogenase (3-HBDH) with improved performance relative to the wild-type 3-HBDH, a nucleic acid encoding the mutant 3-HBDH, a cell comprising the mutant 3-HBDH or the nucleic acid, a method of determining the amount or concentration of 3-hydroxybutyrate in a sample, and a device for determining the amount or concentration of 3-hydroxybutyrate in a sample.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: July 7, 2020
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Daniela Beck, Mara Boenitz-Dulat, Peter Kratzsch, Thomas Streidl, Carina Horn
  • Publication number: 20200087633
    Abstract: The present invention relates to improved variants of variants of the Glucose Dehydrogenases (GlucDH) derived from Bacillus subtilis having improved properties in the presence of cNAD as cofactor, to genes encoding such variant GlucDHs, to proteins of such GlucDH variants, and to different applications of these GlucDH variants, particularly for determining concentrations of sugars, especially of glucose, in samples such as bodily fluids, especially blood.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Applicant: Roche Diabetes Care, Inc.
    Inventors: Mara Boenitz-Dulat, Carina Horn, Peter Kratzsch, Thomas Meier, Markus Rudolph, Bernd Schneidinger
  • Patent number: 10508267
    Abstract: The present disclosure relates to a mutant 3-hydroxybutyrate dehydrogenase (3-HBDH) with improved performance relative to the wild-type 3-HBDH, a nucleic acid encoding the mutant 3-HBDH, a cell having the mutant 3-HBDH or the nucleic acid, and/or a method of determining the amount or concentration of 3-hydroxybutyrate in a sample. Also disclosed is the use of the mutant 3-HBDH for determining the amount or concentration of 3-hydroxybutyrate in a sample, and a device for determining the amount or concentration of 3-hydroxybutyrate in a sample.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: December 17, 2019
    Assignees: Roche Diagnostics Operations, Inc., Roche Diabetes Care, Inc.
    Inventors: Peter Kratzsch, Mara Boenitz-Dulat, Daniela Beck, Thomas Streidl, Stacy Hunt DuVall
  • Patent number: 10190182
    Abstract: Herein is reported a method for producing an enzymatic conjugation product of two polypeptides comprising incubating of a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide has an oligo-alanine Am (m=2 (SEQ ID NO: 26), or 3 (SEQ ID NO: 27), or 4 (SEQ ID NO: 28), or 5 (SEQ ID NO: 29)) amino acid sequence at its N-terminus, a third polypeptide with sortase activity which is derived from Staphylococcus aureus Sortase A, and recovering the conjugate from the reaction mixture and thereby producing the enzymatic conjugation product of two polypeptides.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: January 29, 2019
    Assignee: HOFFMANN LA-ROCHE INC.
    Inventors: Mara Boenitz-Dulat, Peter Kratzsch, Martin Schatte
  • Publication number: 20180346886
    Abstract: The present invention relates to a mutant 3-hydroxybutyrate dehydrogenase (3-HBDH) with improved performance relative to the wild-type 3-HBDH, a nucleic acid encoding the mutant 3-HBDH, a cell comprising the mutant 3-HBDH or the nucleic acid, a method of determining the amount or concentration of 3-hydroxybutyrate in a sample, and a device for determining the amount or concentration of 3-hydroxybutyrate in a sample.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Inventors: Daniela Beck, Mara Boenitz-Dulat, Peter Kratzsch, Thomas Streidl, Carina Horn
  • Publication number: 20180291354
    Abstract: The present disclosure relates to a mutant 3-hydroxybutyrate dehydrogenase (3-HBDH) with improved performance relative to the wild-type 3-HBDH, a nucleic acid encoding the mutant 3-HBDH, a cell having the mutant 3-HBDH or the nucleic acid, and/or a method of determining the amount or concentration of 3-hydroxybutyrate in a sample. Also disclosed is the use of the mutant 3-HBDH for determining the amount or concentration of 3-hydroxybutyrate in a sample, and a device for determining the amount or concentration of 3-hydroxybutyrate in a sample.
    Type: Application
    Filed: June 21, 2018
    Publication date: October 11, 2018
    Applicants: Roche Diagnostics Operations, Inc., Roche Diabetes Care, Inc.
    Inventors: Peter Kratzsch, Mara Boenitz-Dulat, Daniela Beck, Thomas Streidl, Stacy Hunt DuVall
  • Publication number: 20170370913
    Abstract: Herein is reported a method for the detection of a sortase in a sample, comprising the following steps: a) incubating the sample with a first substrate comprising an immobilization tag and a second substrate comprising a detectable label, whereby in the presence of a sortase in the sample a conjugate comprising the immobilization tag and the detectable label is formed, b) immobilizing the conjugate of step a) via/using the immobilization tag to a solid phase, c) detecting the immobilized conjugate via/using the detectable label and thereby detecting the sortase in the sample.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mara Boenitz-Dulat, Erhard Kopetzki, Peter Kratzsch, Martin Schatte
  • Patent number: 9840729
    Abstract: Azo compounds are disclosed that do not form azoxy dimers and that do not have any reactive nitroso groups. Also disclosed are use of the azo compounds as mediators in optical and electrochemical diagnostic methods, as well as detection reagents, kits and test elements that include such azo compounds and that can be used in the diagnostic methods.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 12, 2017
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Stacy H. Duvall, Peter Gebauer, Dieter Heindl, Carina Horn, Peter Kratzsch, Michael Marquant, Thomas Meier
  • Publication number: 20170292166
    Abstract: Herein is reported a method for producing an enzymatic conjugation product of two polypeptides comprising incubating of a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide has an oligo-alanine Am (m=2 (SEQ ID NO: 26), or 3 (SEQ ID NO: 27), or 4 (SEQ ID NO: 28), or 5 (SEQ ID NO: 29)) amino acid sequence at its N-terminus, a third polypeptide with sortase activity which is derived from Staphylococcus aureus Sortase A, and recovering the conjugate from the reaction mixture and thereby producing the enzymatic conjugation product of two polypeptides.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 12, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mara Boenitz-Dulat, Peter Kratzsch, Martin Schatte
  • Publication number: 20140212903
    Abstract: Azo compounds are disclosed that do not form azoxy dimers and that do not have any reactive nitroso groups. Also disclosed are use of the azo compounds as mediators in optical and electrochemical diagnostic methods, as well as detection reagents, kits and test elements that include such azo compounds and that can be used in the diagnostic methods.
    Type: Application
    Filed: March 27, 2014
    Publication date: July 31, 2014
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Stacy H. Duvall, Peter Gebauer, Dieter Heindl, Carina Horn, Peter Kratzsch, Michael Marquant, Thomas Meier
  • Patent number: 7781196
    Abstract: The present invention relates to a mutant protein of PQQ-dependent s-GDH characterized in that in at least one of the positions 122 and 124 the amino acid lysine is present, wherein these positions correspond to the amino acid positions known from the A. calcoaceticus s-GDH wild-type sequence (SEQ ID NO: 2), it also discloses genes encoding such mutant s-GDH, and different applications of these s-GDH mutants, particularly for determining the concentration of glucose in a sample.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: August 24, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Mara Boenitz-Dulat, Peter Kratzsch, Rainer Schmuck
  • Patent number: 7732179
    Abstract: A mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) is provided with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alamine or serine, wherein said mutant additionally comprises, at least one mutation for improving the stability of the mutant and one or more mutation(s) for improving the affinity of the mutant to glucose, and/or one or more mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose, and wherein position 348 correspond to the amino acid positions known from the A. calcoaceticus s-GDH wild-type sequence. Also disclosed are genes encoding such mutant s-GDH, and different applications of these s-GDH mutants, particularly for determining the concentration of glucose in a sample.
    Type: Grant
    Filed: October 13, 2008
    Date of Patent: June 8, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Mara Boenitz-Dulat, Daniela Beck, Peter Kratzsch, Rainer Schmuck, Herbert Von Der Eltz
  • Publication number: 20090305316
    Abstract: The present invention relates to a mutant protein of PQQ-dependent s-GDH characterized in that in at least one of the positions 122 and 124 the amino acid lysine is present, wherein these positions correspond to the amino acid positions known from the A. calcoaceticus s-GDH wild-type sequence (SEQ ID NO: 2), it also discloses genes encoding such mutant s-GDH, and different applications of these s-GDH mutants, particularly for determining the concentration of glucose in a sample.
    Type: Application
    Filed: October 14, 2005
    Publication date: December 10, 2009
    Inventors: Mara Boenitz-Dulat, Peter Kratzsch, Rainer Schmuck
  • Patent number: 7547524
    Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH) comprising an amino acid insertion between positions 428 and 429 as corresponding to the amino acid sequence known from Acinetobacter calcoaceticus, to genes encoding such variant s-GDH, to proteins of such s-GDH variants with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugars, especially of glucose in a sample.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: June 16, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Mara Boenitz-Dulat, Jessica Laggerbauer, Rainer Schmuck, Peter Kratzsch, Wolfgang-Reinhold Knappe
  • Patent number: 7547535
    Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugar, especially of glucose in a sample.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: June 16, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Peter Kratzsch, Rainer Schmuck, Daniela Beck, Zhixin Shao, Detlef Thym, Wolfgang-Reinhold Knappe
  • Publication number: 20090148874
    Abstract: A mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) is provided with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alamine or serine, wherein said mutant additionally comprises, at least one mutation for improving the stability of the mutant and one or more mutation(s) for improving the affinity of the mutant to glucose, and/or one or more mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose, and wherein position 348 correspond to the amino acid positions known from the A. calcoaceticus s-GDH wild-type sequence. Also disclosed are genes encoding such mutant s-GDH, and different applications of these s-GDH mutants, particularly for determining the concentration of glucose in a sample.
    Type: Application
    Filed: October 13, 2008
    Publication date: June 11, 2009
    Inventors: Mara Boenitz-Dulat, Daniela Beck, Peter Kratzsch, Rainer Schmuck, Herbert Von Der Eltz
  • Publication number: 20070243566
    Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH) comprising an amino acid insertion between positions 428 and 429 as corresponding to the amino acid sequence known from Acinetobacter calcoaceticus, to genes encoding such variant s-GDH, to proteins of such s-GDH variants with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugars, especially of glucose in a sample.
    Type: Application
    Filed: July 19, 2005
    Publication date: October 18, 2007
    Inventors: Mara Boenitz-Dulat, Jessica Laggerbauer, Rainer Schmuck, Peter Kratzsch, Wolfgang-Reinhold Knappe
  • Patent number: 7132270
    Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugar, especially of glucose in a sample.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: November 7, 2006
    Assignee: Roche Diagnostics GmbH
    Inventors: Peter Kratzsch, Rainer Schmuck, Daniela Beck, Zhixin Shao, Detlef Thym, Wolfgang-Reinhold Knappe
  • Publication number: 20060148056
    Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugar, especially of glucose in a sample.
    Type: Application
    Filed: December 9, 2005
    Publication date: July 6, 2006
    Inventors: Peter Kratzsch, Rainer Schmuck, Daniela Beck, Zhixin Shao, Detlef Thym, Wolfgang-Reinhold Knappe